ZFHX3

Across TCGA pan-cancer cohorts, ZFHX3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZFHX3 data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZFHX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFHX3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where ZFHX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.302	0.515	.015	14	view →
LUAD	OS	Median	All	1.000	0.798	.018	6	view →
HNSC	DFS	Median	III,IV	0.404	0.712	.038	1	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZFHX3–PDAC (DFS)

Open the PDAC breakdown →